Neffy Nasal Epinephrine Spray Remains Effective Even in Inflamed or Congested Noses
November 9, 2026 10:30 am
A common concern with the needle-free anaphylaxis treatment neffy® (epinephrine nasal spray) is whether it will still work when the nose is inflamed or congested. If a patient has severe nasal allergies or an upper respiratory infection, will the medication still absorb?
Pharmacokinetic and pharmacodynamic (PK/PD) data from clinical studies provide a reassuring answer: neffy maintained therapeutic epinephrine exposure under various compromised nasal conditions, including inflammation, allergic rhinitis, mucus, and infectious states.
Allergies and Allergen-Induced Rhinitis
In clinical studies, researchers induced acute allergic rhinitis by spraying a purified antigen into the nose. This created significant inflammation and rhinorrhea (runny nose).
● Absorption and efficacy
A single 2 mg dose of neffy showed a more rapid initial absorption rate under these conditions compared with normal nasal conditions. This is consistent with the idea that acute allergic inflammation increases the permeability of nasal mucosal blood vessels, allowing epinephrine to enter the bloodstream efficiently. Early exposure (the window most critical for treating anaphylaxis) was comparable to or greater than that seen with intramuscular epinephrine in the studies.
● What this means for patients
Having seasonal allergies or an acute allergic flare in the nose does not appear to prevent neffy from delivering therapeutic epinephrine levels.
● Infections and Mucus (The Common Cold)
Additional studies evaluated neffy in people with active infectious upper respiratory tract infections (such as viral colds). These conditions involve thick mucus, congestion, and swollen tissues.
● Efficacy through secretions
Data showed that infectious mucus and congestion did not significantly impair epinephrine absorption. Subjects with active viral infections achieved therapeutic plasma concentrations of epinephrine. In some analyses, peak concentrations were similar to or slightly higher than those seen in healthy controls.
● What this means for patients
A common cold or upper respiratory infection is not expected to block neffy’s ability to deliver an effective dose of epinephrine.
Anatomical Structural Warnings and Exceptions
While neffy performed well with temporary conditions such as colds and allergic rhinitis, the prescribing information includes an important warning about chronic structural nasal issues.
● Nasal polyps and structural blockages
Patients with significant underlying structural changes—such as prominent nasal polyps, a heavily deviated septum, or a history of major nasal surgery—were excluded from the registration studies. Because a dense physical obstruction could prevent the spray from properly contacting the mucosal lining, absorption may be unpredictable in these individuals.
● Clinical recommendation
The FDA and product labeling advise that healthcare providers consider other epinephrine products given by other routes of administration for patients with underlying structural or anatomical nasal conditions. Patients with these issues should discuss the best option with their allergist or prescribing clinician. An allergist can help determine whether neffy is suitable based on individual nasal anatomy and medical history.
Key Takeaways
● PK/PD studies indicate that neffy maintained therapeutic epinephrine exposure during allergen-induced rhinitis and upper respiratory infections.
● Initial absorption was often faster under acute allergic inflammation.
● The presence of mucus and congestion from colds did not significantly impair absorption.
● Patients with chronic structural nasal abnormalities (polyps, major septal deviation, prior nasal surgery) should consult their clinician, as absorption may be unpredictable and an alternative epinephrine product may be preferred.
● Anyone at risk for anaphylaxis should talk with an allergist about the best epinephrine option for their situation. For more on recognizing and managing anaphylaxis, visit our Anaphylaxis page.